AJP - GI Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 294: G1094-G1099, 2008. First published February 28, 2008; doi:10.1152/ajpgi.00534.2007
0193-1857/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/4/G1094    most recent
00534.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Rifai, Y.
Right arrow Articles by Saccone, G. T. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rifai, Y.
Right arrow Articles by Saccone, G. T. P.

NEUROREGULATION AND MOTILITY

The tripeptide analog feG ameliorates severity of acute pancreatitis in a caerulein mouse model

Yusnita Rifai,1 Alison S. F. Elder,1 Colin J. Carati,2 Damian J. Hussey,1 Xin Li,1 Charmaine M. Woods,1 Ann C. Schloithe,1 Anthony C. Thomas,3 Ronald D. Mathison,4 Joseph S. Davison,4 James Toouli,1 and Gino T. P. Saccone1

Departments of 1Surgery, Centre for Neuroscience, 2Anatomy and Histology, and 3Anatomical Pathology, Flinders University, Flinders Medical Centre, Bedford Park, South Australia, Australia; and 4Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, Canada

Submitted 16 November 2007 ; accepted in final form 21 February 2008

Acute pancreatitis (AP) is associated with significant morbidity and mortality; however, there is no specific treatment for this disease. A novel salivary tripeptide analog, feG, reduces inflammation in several different animal models of inflammation. The aims of this study were to determine whether feG reduced the severity of AP and modifies the expression of pancreatic ICAM-1 mRNA during AP in a mouse model. AP was induced in mice by hourly (x12) intraperitoneal injections of caerulein. A single dose of feG (100 µg/kg) was coadministered with caerulein either at time 0 h (prophylactic) or 3 h after AP induction (therapeutic). Plasma amylase and pancreatic MPO activities and pancreatic ICAM-1 mRNA expression (by RT-PCR) were measured. Pancreatic sections were histologically assessed for abnormal acinar cells and interstitial space. AP induction produced a sevenfold increase in plasma amylase, a tenfold increase in pancreatic MPO activity, and a threefold increase in interstitial space, and 90% of the acinar cells were abnormal. Prophylactic treatment with feG reduced the AP-induced plasma amylase activity by 45%, pancreatic MPO by 80%, the proportion of abnormal acinar cells by 30%, and interstitial space by 40%. Therapeutic treatment with feG significantly reduced the AP-induced abnormal acinar cells by 10% and the interstitial space by 20%. Pancreatic ICAM-1 mRNA expression was upregulated in AP and was reduced by 50% with prophylactic and therapeutic treatment with feG. We conclude that feG ameliorates experimental AP acting at least in part by modulating ICAM-1 expression in the pancreas.

salivary gland peptides; inflammation; neutrophils; ICAM-1; pancreas



Address for reprint requests and other correspondence: G. T. P. Saccone, Dept. of General and Digestive Surgery, Flinders Medical Centre, Bedford Park, South Australia, Australia 5042 (e-mail: gino.saccone{at}flinders.edu.au)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.